글로벌 자궁수축제 시장 – 업계 동향 및 2029년까지의 예측

자궁수축제 시장 분석 및 규모

글로벌 자궁수축제 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 이 시장은 주로 낙태 증가와 취약한 여성 인구에 의해 주도됩니다. 또한 생명공학 및 제약 분야 또는 산업의 발전과 더 많은 협업은 시장 성장을 주도하는 몇 가지 영향 요인입니다. 다양한 유형 중에서 옥시토신 은 수유와 분만에 널리 사용되는 약물 중 하나입니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 자궁수축제 시장의 성장률을 분석합니다. 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함됩니다.

시장 정의

자궁수축제는 공식적으로 에크볼릭으로 알려져 있으며, 수축을 일으키고 자궁의 탄력을 증가시키는 치료제입니다. 자궁수축제는 산후 또는 낙태 후 출혈을 치료하고 분만을 유도하는 데 도움이 됩니다.

자궁수축제 시장 범위 및 세분화

Global Uterotonic Agent Market Dynamics

Drivers

• Surge in Abortion Rate

According to WHO, there are about 73 million abortions worldwide each year. 6 out of 10 (61%) of all unwanted pregnancies and 3 out of 10 (29%) of all pregnancies end with an abortion. Global estimates from 2010 to 2014 show that 45% of all  abortions performed are unsafe. Of all unsafe abortions, one-third were performed in the least secure conditions. H. By individuals who are not trained using dangerous and invasive methods.

• Rising Childbirth Using Labor Induction

Increasing childbirth through labor induction is expected to boost the market growth over the forecast period. For instance, as per National Perinatal Information Center’s January 2019 report, induction of labor rates increased by 40% during 1997-2017 in the U.S.

Opportunities

• Rising Incidence of Postpartum Hemorrhage

Higher prevalence of postpartum hemorrhage is expected to boost the market growth. According to the study, ‘Incidence and risk factors for postpartum hemorrhage among transvaginal deliveries at a tertiary perinatal medical facility in Japan’ published in the journal PLoS One in January 2019, it was witnessed that the prevalence of postpartum hemorrhage was 8.7%, and of severe postpartum hemorrhage was 2.1%. This boosts the market growth.

Restraints/Challenges

• Quality Issues

The quality issues associated with the preparation of uterotonic agents could curb the growth of the global uterotonic agent market over a forecast period.

• High Cost

The huge expenditure of these agents surely hamper the market growth.

This global uterotonic agent market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global uterotonic agent market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Uterotonic Agent Market Scope

The global uterotonic agent market is segmented on the basis of drug, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Carboprost
• Mifepristone
• Methylergonovine
• Dinoprostone
• Dinoprostone
• Others

Indication

• Postpartum Hemorrhage
• Abortion
• Labor
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Uterotonic Agent Market Regional Analysis/Insights

The global uterotonic agent market is analysed and market size insights and trends are provided by drug, indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global uterotonic agent market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the established regulatory framework, rising initiatives for women’s health, rise in adoption of newer technologies and presence of refined healthcare infrastructure

Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Uterotonic Agent Market Share Analysis

The global uterotonic agent market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global uterotonic agent market

Key players operating in the global uterotonic agent market include:

• 넥서스 파마슈티컬스(미국)
• 파이저 주식회사(미국)
• Dr. Reddy's Laboratories Ltd(인도)
• 코르셉트(미국)
• 젠바이오프로(미국)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Amneal Pharmaceuticals Inc (미국)
• 루팡(인도)
• 다이이치산쿄 주식회사(일본)
• 페링 BV(스위스)

SKU-53524